Trinity Biotech plc (TRIB)
TRIB Stock Price Chart
Explore Trinity Biotech plc interactive price chart. Choose custom timeframes to analyze TRIB price movements and trends.
TRIB Company Profile
Discover essential business fundamentals and corporate details for Trinity Biotech plc (TRIB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
21 Oct 1992
Employees
380.00
Website
https://www.trinitybiotech.comCEO
John Gillard
Description
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
TRIB Financial Timeline
Browse a chronological timeline of Trinity Biotech plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Sept 2026
EPS estimate is -$0.26, while revenue estimate is $10.31m.
Stock split effective on 24 Jul 2026
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Jun 2026
EPS came in at -$0.23 surpassing the estimated -$0.31 by +25.81%.
Earnings released on 30 Apr 2026
EPS came in at -$0.90 falling short of the estimated -$0.32 by -181.25%, while revenue for the quarter reached $11.06m , missing expectations by -26.24%.
Earnings released on 23 Dec 2025
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%, while revenue for the quarter reached $14.25m , missing expectations by -1.74%.
Stock split effective on 27 Aug 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 Jul 2025
EPS came in at -$2.40 falling short of the estimated -$0.51 by -370.59%, while revenue for the quarter reached $10.98m , beating expectations by +4.53%.
Earnings released on 15 May 2025
EPS came in at -$5.10 falling short of the estimated -$0.28 by -1.72k%, while revenue for the quarter reached $7.58m , missing expectations by -52.65%.
Earnings released on 3 Apr 2025
EPS came in at -$1.24 falling short of the estimated -$0.30 by -311.83%, while revenue for the quarter reached $15.86m , missing expectations by -3.90%.
Earnings released on 15 Nov 2024
EPS came in at -$0.46 surpassing the estimated -$0.54 by +15.16%, while revenue for the quarter reached $15.15m , missing expectations by -8.17%.
Earnings released on 14 Aug 2024
EPS came in at -$0.71 falling short of the estimated -$0.67 by -5.97%, while revenue for the quarter reached $15.84m , beating expectations by +5.62%.
Earnings released on 23 May 2024
EPS came in at -$0.37 surpassing the estimated -$0.60 by +37.67%, while revenue for the quarter reached $14.70m , missing expectations by -8.10%.
Stock split effective on 23 Feb 2024
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Jan 2024
EPS came in at -$0.72 falling short of the estimated -$0.70 by -2.86%, while revenue for the quarter reached $13.43m , missing expectations by -10.48%.
Earnings released on 3 Oct 2023
EPS came in at -$5.00 falling short of the estimated -$0.45 by -1.01k%, while revenue for the quarter reached $13.90m , missing expectations by -4.15%.
Earnings released on 6 Jul 2023
EPS came in at -$0.78 falling short of the estimated -$0.30 by -160.00%, while revenue for the quarter reached $14.83m , beating expectations by +9.84%.
Earnings released on 10 Apr 2023
EPS came in at $0.06 surpassing the estimated -$0.06 by +200.00%, while revenue for the quarter reached $14.83m , missing expectations by -19.84%.
Earnings released on 23 Mar 2023
EPS came in at -$1.33 falling short of the estimated -$0.06 by -2.11k%, while revenue for the quarter reached $18.04m , beating expectations by +0.20%.
Earnings released on 15 Dec 2022
EPS came in at -$0.23 falling short of the estimated -$0.04 by -475.00%, while revenue for the quarter reached $19.50m , beating expectations by +0.01%.
Earnings released on 30 Jun 2022
EPS came in at -$2.00 falling short of the estimated -$0.20 by -900.00%, while revenue for the quarter reached $18.78m , missing expectations by -6.12%.
Earnings released on 11 Apr 2022
EPS came in at $1.50 surpassing the estimated $0.35 by +328.57%, while revenue for the quarter reached $19.53m , missing expectations by -18.65%.
Earnings released on 15 Dec 2021
EPS came in at $2.25 surpassing the estimated $0.40 by +462.50%, while revenue for the quarter reached $22.00m , missing expectations by -11.98%.
Earnings released on 9 Sept 2021
EPS came in at $5.00 surpassing the estimated $0.07 by +7.04k%, while revenue for the quarter reached $25.84m , beating expectations by +7.68%.
TRIB Stock Performance
Access detailed TRIB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
